论文部分内容阅读
本研究的目的在于评价CA-50对消化道肿瘤的诊断价值。作者测定了434例良性或恶性消化道疾病患者血清中CA-50水平,并与CEA和AFP浓度进行比较。于病人术前或肿瘤复发时采集血清标本。用CanAg CA-50 RlA抑制试验或放免试验对CA-50进行定量。AFP和CEA均用双重试验测定。 CA-50水平在胰腺癌患者中最高,约73%患者CA-50浓度大于17Uml~(-1),其中53%CEA水平高于2.5ngml~(-1),32%CEA水平高于10ngml~(-1)。在8例可切除
The purpose of this study was to evaluate the diagnostic value of CA-50 for gastrointestinal cancer. The authors measured the serum CA-50 levels in 434 patients with benign or malignant digestive diseases and compared them with CEA and AFP concentrations. Serum samples are collected before surgery or when the tumor recurs. CA-50 was quantified using the CanAg CA-50 RlA inhibition assay or radioimmunoassay. Both AFP and CEA were measured using a double test. The CA-50 level was highest in patients with pancreatic cancer, and about 73% of patients had a CA-50 concentration greater than 17 Uml -1 , of which 53% had a CEA level higher than 2.5 ngml -1 and a 32% CEA level was higher than 10 ngml~ (-1). In 8 cases can be removed